09:06 AM EDT, 05/28/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) announced Tuesday it has agreed to acquire the rights to NM26, an experimental eczema treatment, from Numab Therapeutics for $1.25 billion in an all-cash deal.
Price: 147.06, Change: +0.09, Percent Change: +0.06